Global Antibody Fragments Market Overview
As per MRFR analysis, the antibody fragments market size was estimated at 7.81 (USD Billion) in 2022.
The antibody fragments market industry is expected to grow from 9.01 (USD Billion) in 2023 to 32.4 (USD Billion) by 2032. The antibody fragments market CAGR (growth rate) is expected to be around 15.28% during the forecast period (2024-2032).
Key Antibody Fragments Market Trends Highlighted
The antibody fragments market is poised for significant growth, driven by the increasing prevalence of chronic diseases, advancements in antibody engineering technologies, and the rising demand for targeted therapies.
The development of bispecific and multi specific antibody fragments, capable of binding to multiple targets, is a key trend, offering enhanced specificity and efficacy. Moreover, the advent of antibody-drug conjugates (ADCs) is creating new opportunities, combining the potency of antibodies with the targeted delivery of cytotoxic agents.
The market is also influenced by the growing adoption of antibody fragments in immuno-oncology applications, where they play a crucial role in the development of cancer immunotherapies. Additionally, the increasing focus on personalized medicine and the rise of companion diagnostics are driving the demand for antibody fragments as biomarkers and therapeutic targets.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Antibody Fragments Market Drivers
Rising Prevalence of Chronic Diseases
The modern global market of antibody fragments is driven by the increasing prevalence of various chronic diseases, including but not limited to cancer, autoimmune disorders, and infectious diseases. A growing number of patients are treated with antibody fragments to replace traditional treatments and achieve better results. First, compared to complete monoclonal antibodies, fragments are smaller and have a higher affinity for the antigen, which contributes to their specific, efficient, and targeted action.
Second, antibody fragments can be made in vitro with the desired properties, which reduce immunogenicity, on-target toxicity, and off-target activity and side effects, such as allergies and anaphylactic shock, in addition to increased selectivity. Third, they are less likely to be associated with unpredictable mutations and changes in the host’s cells, tissues, and organs, which results in a lower toxicity of antibody fragments for patients.
The demand for antibody fragments is likely to be driven by increasing rates of chronic diseases in the decades to come, including cancer and other malignant conditions, autoimmune diseases, and infectious agents. The increasing demand for the product prompts major players to invest in R and further application development.
Technological Advancements
The process of rapid advancements in such biotechnological and molecular biology fields as recombinant DNA technology, phage display libraries, and protein engineering has considerably facilitated the development and availability of novel antibody fragments possessing better properties.
In particular, the application of recombinant DNA enables the generation of appreciable amounts of antibody fragments. Phage display libraries, that screen billions of antibody fragments and select those possessing the necessary specificity and affinity, have also played an important role.
Finally, protein engineering is applied to make structural and functional modifications to antibody fragments, thus increasing their stability, solubility, and/or binding with the target. Therefore, these technology-related changes will contribute to an even higher growth rate of the global antibody fragments market in the forthcoming years. Moreover, the largest market players will benefit from the planned investment in research and development activities and the release of the next generation antibody fragments with better/ unique properties or even new therapeutic applications.
Government Support and Funding
One of the significant factors that influence the growth of the global market of antibody fragments is government support and funding. Health and drug control departments of governments in different countries recognisd the potential of antibody fragments to meet unmet medical needs and provide support to the developers of these drugs.
They provide support in the form of funding, grants, tax incentives etc. Governments encourage the research and development of antibody fragments and their commercialization by offering market exclusivity and smoothing the approval processes of regulatory bodies.
In the years to come, this factor is going to impact the global market of antibody fragments positively because many of the countries around the world are going to continue supporting the development of new technologies that can revolutionize the healthcare industry and deliver better treatment to the patients. As more and more funds are going to be allocated to that area by the governments of different countries, the global market of antibody fragments is going to be one of the primary recipients of that support.
Antibody Fragments Market Segment Insights
Antibody Fragments Market Type Insights
The global antibody fragments market segmentation by type includes Fab fragments, F(ab’)2 fragments, Fv fragments, ScFv fragments, and dAb fragments. Fab fragments accounted for the largest revenue share in 2023, and this trend is anticipated to continue through 2032. The growth of this segment can be attributed to the extensive applications of fab fragments in the development of therapeutic antibodies, diagnostics, and research tools, among others.
F(ab’)2 fragments are expected to experience the fastest growth over the forecast period due to their ability to bind two different antigens, making them particularly useful for applications in immunology and cancer immunotherapy, among others.
Fv fragments are anticipated to exhibit significant growth over the coming years, with their small size and high affinity rendering them suitable for use in antibody engineering and drug targeting. ScFv Fragments are expected to register moderate growth, culminating from their ability to penetrate tissues more easily than larger antibody fragments.
dAb fragments are also anticipated to grow steadily due to their high stability, and they can bind to latent epitopes, making them ideal for use in antibody-based therapeutics and diagnostics. the global antibody fragments market segmentation by type is expected to experience significant growth in the coming years. This growth will be facilitated by the increasing applications of these fragments across different industries, including the engineering of antibodies, drug development, and diagnostics, among others.
Global Antibody Fragments Market, by Type 2023 & 2032 (USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Antibody Fragments Market Source Insights
The global antibody fragments market is projected to grow from 2022 to 2023; the market will be led by the recombinant sources segment, which will account for more than 60% of the global antibody fragments market revenue. Recombinant sources is expected to be the fastest-growing segment during the forecast period, with a CAGR of over 15%.
The increasing acceptance of recombinant antibody fragments in therapeutic applications is expected to fuel the growth of the segment. The Natural Sources segment will hold the second-largest market share in 2023, accounting for more than 25% of the global antibody fragments market revenue.
This segment is expected to grow at a CAGR of over 10%, fueled by the rising demand for natural antibody fragments in research applications. The Synthetic Sources segment will hold the lowest market share in 2023, accounting for less than 15% of the Global Antibody Fragments Market revenue. However, this segment is expected to grow at a CAGR of over 8%, fueled by the rising demand for synthetic antibody fragments in diagnostic applications.
Antibody Fragments Market Application Insights
The global antibody fragments market segmentation by application comprises diagnostics, therapeutics, research tools, bioconjugation, and drug delivery systems. In 2023, the therapeutics segment held the largest share of the market, accounting for around 55.6% of the global antibody fragments market revenue.
The large share of therapeutics can be attributed to the increasing prevalence of chronic diseases and the rising demand for targeted therapies. The diagnostics segment is also expected to witness significant growth during the forecast period due to the growing demand for early disease detection and personalized medicine.
Antibody Fragments Market Target Insights
The global antibody fragments market segmentation by target provides insights into the specific applications of antibody fragments in various therapeutic areas. The major targets include Infectious diseases, cancer, autoimmune disorders, neurological disorders, and cardiovascular diseases. Infectious
Diseases is a significant segment, driven by the increasing prevalence of infectious diseases and the need for effective treatments. Antibody fragments are being developed to target specific pathogens, offering advantages such as high specificity and reduced immunogenicity.
The cancer segment holds a substantial share due to the rising incidence of cancer and the development of targeted therapies. Antibody fragments are used in cancer treatment to deliver cytotoxic agents directly to tumor cells, minimizing systemic toxicity.
Autoimmune disorders is another key segment, with antibody fragments playing a crucial role in modulating immune responses. They are being used to treat conditions such as rheumatoid arthritis and multiple sclerosis. The Neurological Disorders segment is growing due to the increasing prevalence of neurodegenerative diseases.
Antibody fragments are being developed to target specific proteins involved in neurodegenerative processes. The Cardiovascular Diseases segment is also witnessing growth, as antibody fragments are being explored for the treatment of conditions such as atherosclerosis and heart failure. Overall, the Target segment provides a comprehensive view of the specific therapeutic areas where antibody fragments are being utilized and the growth opportunities within each segment.
Antibody Fragments Market Regional Insights
North America dominated the Global Antibody Fragments Market revenue in 2023 and is expected to maintain its dominance throughout the forecast period. The presence of key players, advanced healthcare infrastructure, and high adoption of innovative technologies drive the regional market growth. Europe holds the second-largest share due to the increasing prevalence of chronic diseases, government initiatives to support research and development, and favorable reimbursement policies.
The APAC region is anticipated to witness the fastest growth rate owing to rising healthcare expenditure, growing awareness about antibody fragments, and increasing investments in biotechnology. South America and MEA also contribute significantly to the Global Antibody Fragments Market, with emerging economies such as Brazil, Argentina, and Saudi Arabia showing promising growth potential.
Global Antibody Fragments Market, by Region 2023 & 2032 (USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Antibody Fragments Market Key Players and Competitive Insights
Major players in the antibody fragments market are constantly engaged in the development of innovative products to gain a competitive edge. Leading players are focusing on the development of products and increase production in the regions expected to offer market potential such as Asia Pacific and Latin America.
The antibody fragments market development is being driven by the increasing demand for targeted therapies, advancements in protein engineering techniques, and the growing prevalence of chronic diseases. The competitive landscape is expected to remain highly competitive in the coming years. Major players are focusing on expansion of product portfolio and acquiring smaller companies and startups to gain market share.
A leading company is F. Hoffmann-La Roche Ltd. The company is focused on developing innovative antibody fragments for diseases such as cancer, autoimmune disorders, and infectious diseases. F. Hoffmann-La Roche Ltd. has a strong pipeline of antibody fragments in different stages of development. The company is engaged in agreements with other companies to expand their product range and reach across the globe.
Another major competitor in the antibody fragments market is AbbVie Inc. The company is focused on the development and commercialization of antibody fragments for diseases including cancer, immunology, and neurology. AbbVie Inc. has a strong portfolio of products which includes Humira, one of the highest selling drugs globally. The company is engaged in research and development activities to expand the pipeline of antibody fragment candidates.
Key Companies in the Antibody Fragments Market Include:
- Aldevron
- BioRad Laboratories
- Creative Biolabs
- Genmab
- GenScript
- Merck KGaA
- New England Biolabs
- Agilent Technologies
- Cytivia
- Evotec
- Lonza Group
- Charles River Laboratories
- Bioge
- Promega
- Abcam
Antibody Fragments Market Developments
The global antibody fragments market is projected to reach USD 32.4 billion by 2032, exhibiting a CAGR of 15.28% during the forecast period (2024-2032). The growth of the market is attributed to the increasing prevalence of chronic diseases, rising demand for targeted therapies, and advancements in antibody engineering technologies.
Key recent developments in the market include the approval of novel antibody fragments for the treatment of various diseases, such as cancer and autoimmune disorders. Additionally, strategic collaborations and acquisitions among market players are driving innovation and expanding the product portfolio. The market is expected to witness significant growth in the coming years due to the increasing demand for personalized and effective treatments.
Antibody Fragments Market Segmentation Insights
Antibody Fragments Market Type Outlook
- Fab Fragments
- F(ab')2 Fragments
- Fv Fragments
- ScFv Fragments
- dAb Fragments
Antibody Fragments Market Source Outlook
- Natural Sources
- Recombinant Sources
- Synthetic Sources
Antibody Fragments Market Application Outlook
- Diagnostics
- Therapeutics
- Research Tools
- Bioconjugation
- Drug Delivery Systems
Antibody Fragments Market Target Outlook
- Infectious Diseases
- Cancer
- Autoimmune Disorders
- Neurological Disorders
- Cardiovascular Diseases
Antibody Fragments Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
| Report Attribute/Metric |
Details |
| Market Size 2022 |
7.81 (USD Billion) |
| Market Size 2023 |
9.01 (USD Billion) |
| Market Size 2032 |
32.4 (USD Billion) |
| Compound Annual Growth Rate (CAGR) |
15.28% (2024-2032) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year |
2023 |
| Market Forecast Period |
2024 - 2032 |
| Historical Data |
2019 - 2023 |
| Market Forecast Units |
USD Billion |
| Key Companies Profiled |
Aldevron, BioRad Laboratories, Creative Biolabs, Genmab, GenScript, Merck KGaA, New England Biolabs, Agilent Technologies, Cytivia, Evotec, Lonza Group, Charles River Laboratories, Bioge, Promega, Abcam |
| Segments Covered |
Type, Source, Application, Target, Region |
| Key Market Opportunities |
Immuno-oncology development Research applications Diagnostic applications Aptamers |
| Key Market Dynamics |
Technological advancements Growing demand for targeted therapies Rising prevalence of chronic diseases Increasing R&D investments Expanding applications in diagnostics |
| Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The global antibody fragments market is expected to reach USD 32.4 billion by 2032, exhibiting a CAGR of 15.28% during the forecast period (2023-2032).
North America is expected to dominate the global antibody fragments market throughout the forecast period, owing to the presence of key players, advanced healthcare infrastructure, and high adoption of innovative technologies.
Rising prevalence of chronic diseases, increasing demand for targeted therapies, and technological advancements in antibody engineering are the key growth drivers of the global antibody fragments market.
The oncology segment is expected to hold the largest market share during the forecast period due to the increasing incidence of cancer and the development of novel antibody fragments for cancer treatment.
Key competitors in the global antibody fragments market include AbbVie, Amgen, AstraZeneca, Biogen, Eli Lilly, Johnson & Johnson, Merck, Pfizer, Roche, and Sanofi.
The global antibody fragments market is expected to grow at a CAGR of 15.28% during the forecast period (2024-2032).
Asia Pacific is expected to witness the highest growth rate during the forecast period due to the increasing healthcare expenditure, rising prevalence of chronic diseases, and growing adoption of antibody fragments in various therapeutic applications.
The high cost of antibody fragment production, stringent regulatory requirements, and intellectual property concerns are some of the challenges faced by the global antibody fragments market.
Advancements in antibody engineering, increasing demand for personalized medicine, and the development of novel applications are some of the opportunities for growth in the global antibody fragments market.
The base year is 2023 and the end year is 2032 for the forecast period of the global antibody fragments market.
